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Abstract
Background: Epidemiologic evidence suggests a heritable component to risk for sudden cardiac arrest
independent of risk for myocardial infarction. Recent candidate gene association studies for community sudden
cardiac arrests have focused on a limited number of biological pathways and yielded conflicting results. We sought
to identify novel gene associations for sudden cardiac arrest in patients with coronary artery disease by performing
a genome-wide association study.
Methods: Tagging SNPs (n = 338,328) spanning the genome were typed in a case-control study comparing 89
patients with coronary artery disease and sudden cardiac arrest due to ventricular tachycardia or ventricular
fibrillation to 520 healthy controls.
Results: Fourteen SNPs including 7 SNPs among 7 genes (ACYP2, AP1G2, ESR1, DGES2, GRIA1, KCTD1, ZNF385B)
were associated with sudden cardiac arrest (all p < 1.30 × 10
-7), following Bonferroni correction and adjustment for
population substructure, age, and sex; genetic variation in ESR1 (p = 2.62 × 10
-8; Odds Ratio [OR] = 1.43, 95%
confidence interval [CI]:1.277, 1.596) has previously been established as a risk factor for cardiovascular disease. In
tandem, the role of 9 genes for monogenic long QT syndrome (LQT1-9) was assessed, yielding evidence of
association with CACNA1C (LQT8; p = 3.09 × 10
-4; OR = 1.18, 95% CI:1.079, 1.290). We also assessed 4 recently
published gene associations for sudden cardiac arrest, validating NOS1AP (p = 4.50 × 10
-2, OR = 1.15, 95% CI:1.003,
1.326), CSMD2 (p = 6.6 × 10
-3, OR = 2.27, 95% CI:1.681, 2.859), and AGTR1 (p = 3.00 × 10
-3, OR = 1.13, 95% CI:1.042,
1.215).
Conclusion: We demonstrate 11 gene associations for sudden cardiac arrest due to ventricular tachycardia/
ventricular fibrillation in patients with coronary artery disease. Validation studies in independent cohorts and
functional studies are required to confirm these associations.
Background
Sudden cardiac arrest (SCA) remains a major public
health problem, causing up to 450,000 deaths per year
in the U.S [1]. Approximately 80% of sudden cardiac
deaths (SCDs) occur in the setting of coronary artery
disease (CAD)[2]. Ventricular tachycardia (VT) or ven-
tricular fibrillation (VF) is the initiating event in the
majority of SCAs[3]. Assessment of ejection fraction
(EF) remains the only method to identify patients at risk
for SCA and primary prevention implantable cardiover-
ter-defibrillator (ICD) implantation, but is both insensi-
tive and nonspecific[4]. Several epidemiologic studies
demonstrating that a family history of SCA is an inde-
pendent risk factor for SCA and primary VF suggest a
genetic susceptibility to SCA in the setting of CAD[5-7].
Recent candidate gene association studies for SCA
have yielded conflicting results for common variants in
the ß2 adrenergic receptor gene[8,9], possibly due to dif-
ferent SCA phenotype definitions - community-based
SCA cases as compared to SCA cases due to
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recent candidate gene studies have yielded associations
with SCA for single nucleotide polymorphisms (SNPs)
in angiotensin-converting enzyme pathway genes and
the transforming growth factor ß-receptor 2 gene, but
have yet to be validated[11,12]. A genome wide associa-
tion study (GWAS) reported SNPs in the NOS1AP gene
associated with the prolonged QT interval phenotype, a
surrogate of SCA [13]. Association of these NOS1AP
SNPs with QT interval has been validated in whites but
not blacks from independent cohorts,[13-16] while asso-
ciation with a separate SNP in NOS1AP, not associated
with QT interval, has been reported with SCA [17]. A
GWAS of the SCA/SCD phenotype has not yet been
reported.
The recent report of pilot GWAS of complex traits
[18,19] as a precursor to validation studies in larger
independent cohorts suggests that such studies could
result in cost-effective identification of susceptibility loci
of large effect. Thus, the use of rigorous phenotypic cri-
teria for SCA may bolster the power of GWAS to iden-
tify risk loci. Accordingly, we performed a pilot GWAS
to identify novel genes influencing risk of SCA in a
group of patients with a history of myocardial infarction
(MI) and aborted SCA with documented VT/VF com-
pared to a healthy control group without SCA or ventri-
cular arrhythmias.
Methods
The UCSF Committee on Human Research approved all
protocols. Informed consent was obtained from all parti-
cipants for DNA isolation and plasma collection.
Study Design
Consecutive cases of SCA presenting to University of
California, San Francisco (UCSF) Medical Center Emer-
gency Department or inpatient cases of SCA at UCSF
Medical Center between January 2000 and June 2008
were screened. SCA was defined as a cardiac arrest with
documented sustained monomorphic VT or VF requir-
ing cardioversion or defibrillation, exclusive of torsades
de pointes (drug-induced QT prolongation or other-
wise). Because we were interested in the most common
phenotype of SCA, that occurring the setting of CAD,
only patients with a history of MI were included in this
study. Although all SCA cases had a history of MI,
thirty-six SCA cases occurred in the setting of acute
ischemia while 53 SCA cases occurred in the absence of
active ischemia. Thus SCA cases consisted of 89 Cauca-
sian non-Hispanic patients with aborted SCD and a his-
tory of MI.
The control population originated from three
resources [20]. These were randomly selected, healthy
Caucasian controls without specific information
regarding CAD. Recent large GWAS using shared con-
trols of this type have met with success [20-22]. Sixty
unrelated controls employed by the International Hap-
Map Project http://www.HapMap.org were selected
from the Coriell Institute for Medical Research http://
ccr.coriell.org Human Genetic Data Collection. Two-
hundred and sixteen healthy Caucasian controls were
derived from a large GWAS of narcolepsy [20]. The
remaining 244 controls were healthy Caucasian renal
transplant donors from an ongoing study of the geno-
mics of renal transplantation (NIH U19 AI063603).
Informed consent was obtained from all participants.
Protocols were approved by the local institution review
boards at all participating institutions.
Measurements
Procedures for DNA collection and genotyping using
t h eG e n o m e - W i d eS N PA r r a y6 . 0( A f f y m e t r i x ,S a n t a
Clara, CA) are summarized in the Supplementary Meth-
ods (Additional file 1).
Statistical Analyses
To examine differences in the distribution of demo-
graphic factors between cases and controls, we used the
unequal-variance t-test for age and a chi-square test for
sex. Regression analyses performed to estimate genetic
associations controlling for age, sex, and population
stratification were conducted in STATAv9.0 (StataCorp,
College Station, TX). All other analyses were conducted
using HelixTree (GoldenHelix, Bozeman, MT).
The procedures employed to ensure robust genetic
association analyses of the 319,222 tagging SNPs[21]
including correction for covariates, population substruc-
ture[23,24], and batch effects are described in the Sup-
plementary Methods (Additional file 1). The genetic
models assessed, procedure for haplotype construction
[25] and analyses and significance thresholds established
for genome-wide, validation of prior genetic associations
(i.e., NOS1AP[13-16], KNG1[11], AGTR1[11]), and
novel candidate gene analyses (i.e., monogenic forms of
SCA)[26] are also described in the Supplementary Meth-
ods (Additional files 1, 2, 3, 4, 5 and 6). The procedures
employed to examine the putative function[27,28] of
associations are also described in the Supplementary
Methods (Additional file 1).
Results
Study Population
Compared with controls (Table 1), SCA cases were
older (72.8 ± 12.7 versus 52.8 ± 15.5 years; p < 0.0001)
and predominantly male (92% versus 52%, p < 0.0001).
SCA cases had a mean BMI of 25.8 ± 4.4 kg/m
2 and a
mean EF of 35.6 ± 14.6%. History of congestive heart
failure (CHF) was present in 75.3% of cases; diabetes
Aouizerat et al. BMC Cardiovascular Disorders 2011, 11:29
http://www.biomedcentral.com/1471-2261/11/29
Page 2 of 10mellitus in 27.4% of cases, and hypertension in 81.3% of
cases. Clinical characteristics were not available for the
anonymous healthy controls.
Population Stratification Analysis
The eigenstrat method was utilized to evaluate and
adjust for any potential confounding based on subtle dif-
ferences between groups resulting from differences in
ancestry. Genomic control correction factors ranged
from 1.027 to 1.086, suggesting a relatively homogenous
population. Visual inspection of Q-Q plots of the -log10
P-values generated before and after PCA adjustment,
indicated minimal change in the ratio of observed versus
expected P-values following PCA correction, additional
evidence that population stratification is modest (Addi-
tional files 9, 10 and 11).
GWAS: Identification of Novel Markers for SCA
Manhattan plots of the 319,222 tagSNPs employed to
interrogate the genomes of the study population are
depicted in Figure 1. Fourteen SNPs exceeded the PCA-,
age-, and sex-adjusted Bonferroni significance threshold,
7 of which are located in known genes: ACYP2,
ZNF385B, GRIA1, ESR1, AP1G2, DEGS2, KCTD1
(Table 2). Of note, genetic variation in one of the genes
detected (ESR1) is associated with increased risk of MI
in 2 independent populations [29,30]. Given the modest
sample size of this study, the top 0.1% (n = 300) PCA-
adjusted SNP associations were also tabulated to provide
the opportunity for validation in other populations
(Additional file 12: Table 1). Although many of the 160
genes represented in the top 300 SNP associations are
poorly explored vis a vis cardiovascular biology, it is
noteworthy that one-quarter (n = 41) of these loci are
genes with evidence of a role in cardiovascular pheno-
types, 2 of which are candidate genes with high suspi-
cion for influencing SCA risk, CACNA1C(LQT8) and
Table 1 Demographic Characteristics of SCA Cases and Healthy Controls
Controls
Characteristics SCA Cases All Controls Narcolepsy Renal Donor Hap Map
N 88 517 216 241 60
Age(years) 72.8 ± 12.7 52.8 ± 15.5 59.0 ± 7.5 42.0 ± 13.8 74.0 ± 7.9
Male(%) 92.0 51.8 52.3 51.9 50.0
Congestive Heart Failure(%) 75.3% N/A
Ejection Fraction(%) 35.6 ± 14.6 N/A
Age at index MI(years) 56.6 ± 13.6 N/A
Hypertension(%) 81.3 N/A
Diabetes(%) 27.4 N/A
Current Smoker(%) 10.9 N/A
Body Mass Index(kg/m
2) 25.8 ± 4.4 N/A
A] 
  
B]  
 
C]  
Figure 1 Summary of genome-wide association scan results for
SCA.
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erated after PCA adjustment indicate that all of the SNP
associations listed in Table 2 and Additional file 12
(Table 1)deviate considerably from expected P-values
following PCA correction, additional evidence that these
observations are not likely due to chance (Additional
File 13).
Prior Gene Associations with SCA
In an attempt to validate previous candidate gene asso-
ciations reported for SCA, tagSNPs spanning AGTR1,
CSMD2, KNG1, and NOS1AP were examined. The
tagSNP for each candidate gene with the greatest mag-
nitude of the test statistic is listed in Table 3. We repli-
cated associations for genetic variation in AGTR1 and
NOS1AP but not KNG1. Rs263936 in AGTR1 was asso-
ciated with an increased odds of SCA (adjusted OR =
1.13, 95% CI:1.042-1.215, p = 0.003). According to pub-
lic databases, the risk allele for SCA in AGTR1
(rs1492099) recently identified[11] is estimated to be in
poor linkage disequilibrium (LD) with rs2639365 (r
2 =
0.011) in Caucasians. Rs4292933 in NOS1AP was asso-
ciated with an increased odds of SCA (adjusted OR =
1.15, 95% CI:1.003-1.326, p = 0.045). Though not
directly ascertained in our sample, rs4292933 is not in
LD with the previously reported NOS1AP risk alleles for
QT interval (rs10494366, r
2 = 0.091)[13,14] and those
SNPs with reported association with SCD (rs12567209
[r
2 = 0.245], rs16847548 [r
2 = 0.096])[17] in the Cauca-
sian populations sampled in public databases. We also
replicated an association with SCA risk for SNP
rs1325258 in the CSMD2 gene (adjusted OR = 2.27,
95% CI:1.681, 2.859, p = 0.0061), one of 6 genes meeting
significance threshold of p < 10
-4 (but not genome-wide
significance) in Oregon-SUDS GWAS on SCD but not
validated in ARIC/CHS [33].
Long QT Genes
To ascertain if population variation in genes underlying
monogenic long QT SCD syndromes is associated with
SCA, tagSNPs spanning KCNQ1 (LQT1), SCN5A (LQT3),
ANK2 (LQT4), KCNE1 (LQT5), KCNE2 (LQT6), KCNJ2
(LQT7), CACN1AC (LQT8), and CAV3 (LQT9) were
examined. The tagSNP for each candidate gene with the
greatest magnitude of the test statistic is listed in Table 3.
Rs7132154 in CACN1AC (LQT8) was associated with
SCA (adjusted OR = 1.18, 95% CI:1.08-1.29, p = 0.0003).
Suggestive evidence of association, defined as a gene-wise
permutation p<0.05, was observed for rs2834455 in
KCNE2 (LQT6) and rs6422142 in KCNQ1 (LQT1).
Localization of Genetic Associations Using Haplotype
Analysis
To evaluate genetic associations that involved more than
one tagSNP and to localize the association signals for
the genes listed in Tables 2 and 3, haplotype analyses
were conducted. The results of the haplotype analyses,
using a sliding window approach, are summarized in
Table 4. Haplotype analyses for ACYP2, AP1G2, CAC-
NA1C, NOS3, and NOS1AP failed to improve on the
initial association signal, and are thus not listed. For
ZNF385B, two regions were identified.
Table 2 SNPs meeting genome-wide significance threshold after correction for population stratification, age, and sex
Gene rsID PPCA PUNADJ ORPCA-ADJ (95% CI) PPCA-ADJ MAF Call Rate PHWE Region Position
ACYP2 rs1559040 1.04E-09 2.11E-06 1.54(1.320,1.787) 3.76e-08 0.111 0.990 1.000000 2p16.2 54201254
ZNF385B rs16866933 1.45E-15 1.54E-10 1.69(1.475,1.925) 6.15e-14 0.085 0.977 0.059204 2q31.2 180274923
rs4621553 2.18E-08 5.49E-06 1.40(1.243,1.578) 4.12e-08 0.220 0.995 0.001665 5q22.2 113058063
GRIA1 rs12189362 2.23E-12 9.94E-09 1.50(1.322,1.693) 3.22e-10 0.117 0.977 0.242562 5q33.2 153037741
ESR1 rs2982694 3.91E-12 2.62E-08 1.43(1.277,1.596) 6.96e-10 0.138 0.975 0.160104 6q25.1 152327380
rs10765792 5.69E-15 4.89E-10 1.54(1.369,1.724) 8.47e-13 0.111 0.980 0.031706 11q21 95506348
rs7307780 2.27E-16 3.11E-12 1.45(1.327,1.592) 5.03e-15 0.186 0.960 0.141220 12q21.2 74506885
rs12429889 8.93E-23 7.08E-16 1.64(1.479,1.812) 5.28e-20 0.161 0.954 1.000000 13q22.1 73640323
AP1G2 rs2281680 5.45E-06 1.54E-04 1.38(1.227,1.542) 6.05e-08 0.212 0.982 0.260456 14q11.2 23102910
rs11624056 8.59E-10 1.20E-06 1.43(1.260,1.615) 3.00e-08 0.110 0.967 0.028261 14q31.3 86576001
DEGS2* rs7157599 9.14E-09 6.98E-11 1.13(1.082,1.185) 1.30e-07 0.312 0.952 0.830456 14q32.2 99695655
rs17718586 1.70E-08 7.26E-06 1.53(1.324,1.775) 1.70e-08 0.101 0.964 0.424883 17q24.3 66155784
rs597503 1.49E-11 1.33E-07 1.45(1.273,1.646) 2.34e-08 0.127 0.959 0.668482 18p11.31 6929947
KCTD1 rs16942421 9.11E-11 3.33E-07 1.68(1.429,1.981) 7.75e-10 0.081 0.975 0.742069 18q11.2 22410423
Unless otherwise indicated, a recessive genetic model fit the data best.
* A dominant genetic model fit the data best.
Abbreviations: rsID, Reference Sequence IDentifier for a given single nucleotide polymorphism (SNP); PPCA, p-value for the PCA-corrected test statistic (i.e., Trend
Test for the Additive model, Fisher’s Exact Test for Dominant and Recessive Models); PUNADJ, p-value for the unadjusted test statistic (i.e., Correlation); ORPCA-ADJ
(95% CI), the odds ratio and 95% confidence interval for the test statistic; PPCA-ADJ, p-value for the test statistic adjusted for PCA, age, and sex; MAF, minor allele
frequency; PHWE, p-value for the Hardy-Weinberg test statistic; Region; chromosomal position for the variation; Position, nucleotide position for the variation.
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The functional impact of sequence variation in the 14
S N P sm e e t i n gg e n o m ew i d es i g n i f i c a n c ea n dt h ep e r -
muted gene-wise significant SNPs in CACNA1C, NOS3,
NOS1AP, CSMD2 and AGTR1 was assessed, revealing
that rs7157599 in DEGS2 is a nonsynonymous coding
SNP with predicted exonic splicing enhancer effects,
residing within a highly-conserved region. The func-
tional impact of the serine to asparagine change (S8N)
in DEGS2 is predicted to be benign. Rs12429889,
rs17718586, rs16866933 (ZNF385B), rs12189362
(GRIA1), rs2281680 (AP1G2), and rs7132154 (CAC-
NA1C) all reside within highly-conserved regions; the
remainder had no predicted impact. Interrogation of the
PANTHER database for these 7 genes revealed that each
is predicted to have distinct molecular functions and
participates in different biological processes including
cation transport (ACYP2), nerve-nerve presynaptic
transmission (GRIA1), steroid hormone-mediated signal-
ing (ESR1), receptor-mediated endocytosis (AP1G2),
cation transport (KCTD1), mRNA transcriptional regu-
lation (ZNF385B), and metabolism (DEGS2).
Discussion
We demonstrate novel associations in 14 SNPs and SCA
due to malignant ventricular arrhythmias in the setting
of CAD. Seven of these SNPs were in regions without
known genes or regulatory sequences, while the remain-
ing 7 SNPs were located within genes encoding an acyl-
phosphatase (ACYP2), a zinc-finger protein (ZNF385B),
a glutamate receptor 1 (GRIA1), an adaptin subunit
(AP1G2), a sphingolipid enzyme (DEGS2), a neural
potassium channel domain (KCTD1), and an estrogen
receptor (ESR1). In tandem, we assessed SNPs in 9 LQT
genes and 4 candidate genes with recently reported
associations with SCA risk, validating AGTR1, CSMD2,
a n dN O S 1 A Pb u tn o tK N G 1 .A l t h o u g hn o tm e e t i n g
genome-wide significance, notable among the top 0.1%
(n = 300) SNP associations, which included 160 genes,
were 1 SNP in CACNA1C (LQT8) and 3 SNPs in
NOS3. SNP associations in both of these genes met per-
muted gene-wise significance and both genes have
strong mechanistic rationale as candidate genes for SCA.
Although we included a modest number of cases,
t h e s ew e r er i g o r o u s l yp h e n o t y p e d ,a l lw i t hc o n f i r m e d
CAD and aborted SCA due to documented VT/VF, and
were compared to healthy controls without SCD. The
requirement for VT/VF in all SCA cases maximizes the
power of the study by avoiding the possibility of associa-
tion with other spurious causes of out-of-hospital sud-
den death (i.e., pulmonary embolus, bradycardia, acute
heart failure). SCD as defined in prior studies[33], a sud-
den pulseless condition of cardiac origin in a previously
stable individual,[17] is more heterogeneous and neces-
sarily includes many noncardiac and/or nonarrhythmic
causes of sudden death misclassified as SCD [10].
Because we used shared controls, principal components
analysis was employed to exclude the possibility of
population stratification as a cause of spurious associa-
tion. Although we did not test our SNP associations in a
validation cohort, we found associations in genes with
high prior likelihood of mediating SCA risk in the set-
ting of CAD (ESR1, CACNA1C, NOS3) and our replica-
tion of associations with SCA risk for genetic variation
Table 3 Candidate Gene Associations
Gene rsID PPCA PCRUDE ORADJ (95% CI) PADJ MAF Call Rate PHWE Region Position
a) Mechanistic candidates from the top 300 SNPs
CACNA1C
†(LQT8) rs7132154 9.29E-05 4.72E-04 1.18(1.079,1.290) 3.09E-04 0.262 0.992 1.000000 12p13.33 2331484
NOS3 rs17173656 5.41E-05 3.09E-04 1.13(1.068,1.190) 1.53E-05 0.102 1.000 0.786064 7q36.1 150229592
b) Candidate genes for SCA with evidence from the literature
AGTR1* rs2639365 6.16E-04 6.20E-04 1.13(1.042,1.215) 3.00E-03 0.059 0.998 0.317805 3q24 149783168
CSMD2 rs1325258 2.64E-04 5.74E-04 2.27(1.681, 2.859) 6.10E-03 0.095 0.995 0.768301 1p35.1 34250168
KNG1 rs1624230 3.30E-01 2.22E-01 0.99(0.936,1.036) 5.60E-01 0.130 0.974 0.336813 3q27.3 187921629
NOS1AP
† rs4292933 3.90E-02 1.19E-02 1.15(1.003,1.326) 4.50E-02 0.189 0.998 0.109458 1q23.3 160417164
c) Candidate genes for SCA found in monogenic SCD syndromes (LQT genes)
ANK2(LQT4)
† rs399754 5.17E-03 4.96E-03 1.14(1.052,1.244) 2.00E-03 0.328 0.964 0.117906 4q26 114311766
CAV3(LQT9)
† rs17788626 4.63E-01 4.96E-01 1.00(0.932,1.076) 9.69E-01 0.371 0.998 0.851542 3p25.3 8731423
KCNE1(LQT5) rs11702354 2.04E-02 2.25E-02 0.96(0.924,1.00) 4.90E-02 0.277 0.957 0.152965 21q22.12 34806395
KCNE2(LQT6) rs2834455 5.09E-04 1.28E-03 1.08(1.026,1.128) 2.00E-03 0.145 0.987 0.565697 21q22.11 34631628
KCNJ2(LQT7)
† rs12449606 2.27E-02 2.12E-02 1.12(1.024,1.236) 1.40E-02 0.250 0.998 0.625543 17q24.3 65660406
KCNQ1(LQT1)
† rs2237877 2.21E-02 1.49E-02 1.17(1.062,1.295) 2.00E-03 0.226 1.000 0.433296 11p15.5 2722810
SCN5A(LQT3)* rs6422142 1.57E-03 1.92E-03 1.11(1.044,1.178) 1.00E-03 0.102 1.000 0.786064 3p22.2 38678162
Unless otherwise indicated, an additive genetic model fit the data best.*A dominant genetic model fit the data best.
† A recessive genetic model fit the data best.
Markers (SNPs) attaining a gene-wide permutation p < 0.01 are rendered in italicized bold font; markers attaining a gene-wide permutation p < 0.05 are
rendered in italics. Abbreviations: as in Table 2.
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AGTR1) substantiates the value of this study. Moreover,
our conservative approaches vis a vis analytic methodol-
ogy (i.e., PCA-correction, QC criteria) and significance
thresholds (i.e., Bonferroni correction, permutation) sug-
gests that the findings are robust. In contrast to the
recent GWAS on SCD which did not discover any
genetic associations meeting genome-wide significance
[33], we report 7 SNP associations surpassing this strin-
gent threshold.
Little is known about the potential roles of ACYP2,
ZNF385B, GRIA1, AP1G2, DEGS2, and KCTD1 in car-
diovascular physiology. A large body of evidence sup-
ports the impact of estrogen receptor alpha (ESR1),
which regulates the expression of multiple genes after
activation by estrogen, in cardiovascular disease in both
men and women. A higher risk of ischemic cardiac
event has been reported for 2 separate nonsynonymous
SNPs in ESR1 [29,30]. In postmenopausal women, car-
riers of ESR1 haplotype 1 also have a higher risk of
death from such events, although it is unknown whether
these represent sudden deaths due to ventricular
arrhythmias. Rs2982694 is not predicted to result in
functional change in ESR1 and is not in LD with the
prior studied ESR1 SNPs (rs2234693 [r
2 =0 . 0 0 0 ] ,
rs9340799 [r
2 = 0.000]) in Caucasians. We had too few
women to study them separately; however, adjustment
for sex in the regression analyses did not appreciably
change our results (data not shown). Whether our
results represent association of genetic variation in ESR1
with the intermediate phenotype CAD rather than SCA
requires further investigation.
Because of prior evidence, our threshold for signifi-
c a n c ef o rS N P si nt h ep r e v i o u s l ys t u d i e dg e n e s
NOS1AP, CSMD2, AGTR1, and KNG1 was p<0.05.
Association of SNPs in NOS1AP has been consistently
reported with the intermediate phenotype of prolonged
Q Ti n t e r v a l si nC a u c a s i a n sa sw e l la sS C D[ 1 3 - 1 7 ] .
Rs4292933 in NOS1AP in the present study, appears to
be distinct from those studied previously (i.e., they are
not in LD). We also found an association with SCA risk
in the setting of CAD for 2 SNPs in CSMD2, validating
one of top gene associations in the Oregon-SUDS dis-
covery phase of the recent GWAS, but which was not
validated in ARIC or CHS [13]. This may reflect the fact
that our SCA cohort is more similar to the Oregon-
SUDS cohort, both of which required documented
CAD, than the validation ARIC and CHS cohorts which
included more heterogeneous SCD cases, thus restrict-
ing the power to replicate associations with SCA/SCD
in the setting of CAD. Among reported associations
with SCA for SNPs in genes in the angiotensin-convert-
ing enzyme-associated pathway[11], we replicated the
role of genetic variation in AGTR1, but not KNG1.
We separately assessed tagSNPs in 9 long QT genes
causing forms of the monogenic long QT syndrome
which carry high risk for SCD and thus high prior ratio-
nale for association with SCA. In addition to rs7132154
in CACNA1C(LQT8) which was among the top 300
SNP associations and met gene-wise permuted signifi-
cance p<0.01, rs6422142 in KCNQ1(LQT1) and
rs2834455 in KCNE1(LQT6) were associated with
increased odds of SCA at the gene-wise permutation
threshold p<0.05. These SNPs are not predicted to have
functional impact and are presumed to be in LD with
the causative variant(s).
Because we employed highly conservative Bonferroni
correction to arrive at the 14 SNPs meeting genome-
wide significance and limited power to detect additive
effects due to the sample size, we may have missed
some associations with SCA; we thus report the top 300
Table 4 Localization of Associations by Haplotype
Analyses
Gene rs ID PPERMUTE Haplotypes Frequency
AGTR1 rs903051 0.0157 AA 0.616
rs17762633 GA 0.257
GC 0.127
DEGS2 rs2895845 0.0003 GC 0.688
rs7157599 GT 0.312
ESR1 rs3003922 0.0004 GTGTAGG 0.638
rs7748205 GCATGGG 0.130
rs3020396 CTACGGG 0.068
rs3003924 CTACGTA 0.068
rs1884051 CTACGTG 0.040
rs2982694 CTGTATG 0.020
rs3020327
GRIA1 rs7714428 0.0428 ACT 0.338
rs12189362 CCT 0.300
rs10041275 CCC 0.241
rs17115017 CTT 0.105
rs17115018 CTC 0.011
KCTD1 rs10853666 0.0765 CG 0.582
rs16942421 TG 0.337
TT 0.068
CT 0.013
ZNF385B rs9973399 0.0012 CCT 0.516
rs6744352 CCG 0.295
rs2271759 CAT 0.119
rs6708300 AAT 0.053
rs10183243 ACT 0.015
rs16866933 0.0002 A 0.085
Haplotypes rendered in bold and italics differ significantly between cases and
controls (p < 0.05). The size of the window is indicated by the number of
markers listed for a given block. Haplotype analysis for ACYP2, AP1G2,
CACNA1C, NOS3, and NOS1AP failed to improve on the initial association
signal. Haplotype analysis was not performed for CSMD2. For ZNF385B, two
regions were identified. Abbreviations: Frequency, the frequency of each
haplotype; PPERMUTE, p-value for the gene-wise sliding window.
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nity for validation in other populations. These SNPs
reside in 160 known genes, 41 of which have been
reported to play a role in cardiovascular physiology and/
or are expressed in the heart. Of these, we found 1 SNP
(rs7132154) in CACNA1C and 3 SNPs (rs17173656,
rs17173658, rs10264084) in NOS3 that met gene-wise
permutation significance thresholds; these two genes
have key roles in arrhythmogenesis. Mutations in CAC-
NA1C, which encodes the alpha 1C subunit of the vol-
tage-dependent, L-type calcium channel, lead to lack of
voltage-dependent inactivation and prolonged inward
calcium current and cause Timothy syndrome (LQT8), a
multisystem disorder characterized by long QT intervals
and cardiac, hand/foot, facial, and neurodevelopmental
features; malignant VT is present in 80% and are the
leading cause of death [32]. Functional changes in
caveolar-localized endothelial NOS have been identified
post-MI and NOS3-deficient mouse models have
demonstrated a higher incidence of spontaneous and
inducible VT/VF [31]. Intriguingly, NOS3 regulates the
activity of L-type calcium channels (CACNA1C com-
prises the pore-forming subunit) via the ß-adrenergic
system, impacting contractility and excitability [34].
Reduction or elimination of NOS3-produced nitric
oxide, which by itself attenuates b-adrenergic stimula-
tion of L-type calcium channel currents[34], causes
higher influx of calcium ions which can lead to two
potent triggers of ventricular arrhythmias: early and
delayed afterdepolarizations [35]. Thus, although
NOS1AP does not directly bind NOS3, both directly
affect L-type calcium current [36]. Therefore, taken
together these CACNA1C, NOS3, and NOS1AP SNPs
may represent a key electrophysiologic pathway (L-type
calcium current) enriched for risk genotypes for SCA.
Although none of the SNPs in CACNA1C and NOS3
are predicted to have functional impact, rs7132154 in
CACNA1C is in a highly-conserved region; presumably
these SNPs are in LD with the causal variant(s). Further
study is necessary to fine-map these loci, identify causa-
tive variants, and elucidate their impact on CACNA1C
and NOS3 function or levels, signaling, L-type calcium
current, and whether they ultimately affect development
of ventricular arrhythmias.
There are notable limitations to our study. We exam-
ined tagSNPs in genes covered by the DNA SNP array,
rarer polymorphisms and insertion/deletion variants
were not assessed by our study. Stringent control for
the number of statistical tests substantially reduces
power, in particular given the limited number of SCA
cases, such that some associations in the examined
SNPs may have been missed. However, these same strin-
gent procedures increase the confidence that the asso-
ciation signals detected represent true positive results.
Furthermore, because only Caucasian cases and controls
were examined, further studies are needed to determine
whether these findings can be generalized to SCA in
other ethnicities. Healthy controls were used, thus a
confounding association with CAD or other intermedi-
ate phenotypes such as CHF or hypertension cannot be
ruled out. Finally and most importantly, the possibility
that these associations are due to chance should be con-
sidered, thus validation of these findings in independent
populations is critical.
Conclusion
In summary, the results of this pilot GWAS provide
novel evidence for increased arrhythmic SCA risk in the
setting of CAD due to genetic variation in six genes
without prior evidence of cardiovascular effect (ACYP2,
ZNF385B, GRIA1, AP1G2, DEGS2, KCTD1) and in a
number of genes with strong prior evidence of arrhyth-
mic and/or cardiovascular effects (ESR1, CACNA1C,
NOS3, NOS1AP, CSMD2, AGTR1, KCNQ1, KCNE1).
These findings contribute to accumulating evidence for
the influence of genetic variation in risk of SCA due to
malignant ventricular arrhythmias in CAD patients. If
these results are validated, further investigation of these
variants in the development of ventricular arrhythmias
is warranted.
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